We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

105 hedge funds and large institutions have $80.4M invested in Sanofi Contingent Value Rights in 2018 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 19 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 105 → 105 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

10% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 10

26% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 19

45% less capital inflows, than outflows

Capital inflows: $871K | Capital outflows: $1.59M

Holders
105
Holders Change
–
Holders Change %
0%
% of All Funds
2.39%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
9
Increased
14
Reduced
19
Closed
10
Calls
$2​K
Puts
–
Net Calls
+$2​K
Net Calls Change
-⁠$722​K

GCVRZ Hedge Fund Activity: Q3 2018 in Review

105 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q3 2018, worth a combined $80.4M — up 5.6% from $76.2M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of GCVRZ and 9 opened new positions — a net loss of 1 holder — while 19 trimmed existing stakes and 14 added.

The largest buyer was Highbridge Capital Management, adding an estimated $448K. The largest seller was Pomelo Capital, exiting entirely with an estimated $683K sold.

  • 105 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q3 2018, unchanged from Q2 2018.
  • Funds reported $80.4M of Sanofi Contingent Value Rights stock for Q3 2018, up 5.6% quarter-over-quarter.
  • 9 funds opened new Sanofi Contingent Value Rights positions in Q3 2018 and 10 closed out, a net change of -1 holder.
  • The largest Sanofi Contingent Value Rights buyer in Q3 2018 was Highbridge Capital Management, an estimated $448K added.
  • The largest Sanofi Contingent Value Rights seller in Q3 2018 was Pomelo Capital, an estimated $683K sold.

Based on aggregated 13F filings for Q3 2018.